1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Hypoglycemia - Pipeline Review, H1 2017

Hypoglycemia - Pipeline Review, H1 2017

  • February 2017
  • -
  • Global Markets Direct
  • -
  • 66 pages

Hypoglycemia - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoglycemia – Pipeline Review, H1 2017, provides an overview of the Hypoglycemia (Metabolic Disorders) pipeline landscape.

Hypoglycemia is a condition characterized by an abnormally low level of blood sugar (glucose). Symptoms of hypoglycemia include tachycardia, anxiety, shaking, and irritability, feelings of hunger, weakness, tiredness, dizziness, headache, confusion, and trouble concentrating. Risk factors include drug or alcohol consumption, older age, longer duration of diabetes, renal disease, peripheral neuropathy, obesity and cognitive dysfunction.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypoglycemia – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hypoglycemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypoglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 5, 4, 1 and 1 respectively.

Hypoglycemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoglycemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hypoglycemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypoglycemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypoglycemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypoglycemia (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypoglycemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypoglycemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Hypoglycemia - Pipeline Review, H1 2017
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hypoglycemia - Overview
Hypoglycemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hypoglycemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypoglycemia - Companies Involved in Therapeutics Development
Eiger BioPharmaceuticals Inc
Eli Lilly and Company
Heptares Therapeutics Ltd
Novartis AG
Therakind Ltd
USV Pvt Ltd
Vectura Group Plc
XERIS Pharmaceuticals Inc
XOMA Corp
Zealand Pharma AS
Zucara Therapeutics Inc
Hypoglycemia - Drug Profiles
dasiglucagon - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Drug for Hypoglycemia - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
exendin-(9-39) - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
glucagon biosimilar - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
LY-3143753 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
LY-3185643 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
LY-900018 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
pasireotide - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
PRL-2903 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Recombinant Peptide 1 to Agonize Glucagon Receptor for Hypoglycemia - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Recombinant Peptide to Agonize Glucagon Receptor for Hypoglycemia - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia and Congenital Hyperinsulinism - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
terbutaline sulphate MR - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
XOMA-129 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
XOMA-358 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Hypoglycemia - Dormant Projects
Hypoglycemia - Discontinued Products
Hypoglycemia - Product Development Milestones
Featured News and Press Releases
Jan 31, 2017: XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery
Dec 13, 2016: Zealand initiates Phase IIa clinical trial with dasiglucagon in a dual-hormone artificial pancreas system from Beta Bionics
Dec 12, 2016: Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia
Nov 29, 2016: Eiger Updates Progress in Clinical Development Program for Exendin 9-39 to Treat Post-Bariatric Hypoglycemia
Oct 17, 2016: Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency
Sep 15, 2016: XOMA Provides Update from Ongoing Phase 2 XOMA 358 Clinical Studies
Sep 06, 2016: XOMA to Host XOMA 358 Clinical Update Webcast and Conference Call on September 15, 2016
Aug 11, 2016: Phase II results with dasiglucagon (ZP4207) support its potential for use in a ready-to-use rescue pen to treat severe hypoglycemia in diabetes
Jun 13, 2016: Eiger Announces Positive Clinical Results of Single Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Post-Bariatric Hypoglycemia
May 10, 2016: Eiger Announces First Patient Dosed in Phase 2 Multiple Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Hypoglycemia Post-Gastric Bypass Surgery
Apr 27, 2016: XOMA Initiates XOMA 358 Proof-of-Concept Study in Patients with Hypoglycemia Post Gastric Bypass Surgery
Apr 04, 2016: XOMA Presented First Data from Novel Antibody Fragment to Address Severe Acute Hypoglycemia at the ENDO Meeting
Feb 04, 2016: Zealand initiates dosing of patients in Phase 2 with its stable glucagon analogue, ZP4207, for hypoglycemia in diabetes
Oct 26, 2015: XOMA Initiates Proof-of-Concept Study for XOMA 358 in Patients with Congenital Hyperinsulinism
Sep 09, 2015: Results from a multiple-dose Phase Ib trial support the potential of Zealand's stable glucagon analogue, ZP4207, for the correction of mild to moderate hypoglycemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hypoglycemia, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Hypoglycemia - Pipeline by Eiger BioPharmaceuticals Inc, H1 2017
Hypoglycemia - Pipeline by Eli Lilly and Company, H1 2017
Hypoglycemia - Pipeline by Heptares Therapeutics Ltd, H1 2017
Hypoglycemia - Pipeline by Novartis AG, H1 2017
Hypoglycemia - Pipeline by Therakind Ltd, H1 2017
Hypoglycemia - Pipeline by USV Pvt Ltd, H1 2017
Hypoglycemia - Pipeline by Vectura Group Plc, H1 2017
Hypoglycemia - Pipeline by XERIS Pharmaceuticals Inc, H1 2017
Hypoglycemia - Pipeline by XOMA Corp, H1 2017
Hypoglycemia - Pipeline by Zealand Pharma AS, H1 2017
Hypoglycemia - Pipeline by Zucara Therapeutics Inc, H1 2017
Hypoglycemia - Dormant Projects, H1 2017
Hypoglycemia - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Hypoglycemia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50) - Pipeline Review, H2 2016

Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase ...

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H2 2016

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis I (MPS ...

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline Review, H2 2016

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.